ABVC Biopharma Files S-1 Registration Statement

TL;DR

<b>ABVC Biopharma has filed an S-1 registration statement with the SEC, signaling potential future stock offerings.</b>

AI Summary

ABVC BIOPHARMA, INC. (ABVC) filed a IPO Registration (S-1) with the SEC on January 12, 2024. ABVC Biopharma, Inc. filed an S-1 registration statement with the SEC on January 12, 2024. The filing indicates the company is incorporated in Nevada with its principal executive offices in Fremont, California. The company's IRS Employer Identification Number is 26-0014658. The filing is related to a registration statement with number 333-271416. The company was formerly known as American BriVision (Holding) Corp.

Why It Matters

For investors and stakeholders tracking ABVC BIOPHARMA, INC., this filing contains several important signals. This S-1 filing is a prerequisite for public offerings of securities, indicating ABVC Biopharma's intent to raise capital or provide liquidity through the stock market. The filing provides detailed corporate information, including its legal structure, principal business address, and former names, which is crucial for investors to assess the company's history and operational base.

Risk Assessment

Risk Level: low — ABVC BIOPHARMA, INC. shows low risk based on this filing. The filing is a standard S-1 registration statement, which is a preliminary step for public offerings and does not inherently contain new financial performance data or significant operational updates that would indicate immediate high risk.

Analyst Insight

Investors should monitor future filings related to this S-1 for details on proposed offerings, share prices, and the use of proceeds.

Key Numbers

• 2024-01-12 — Filing Date (S-1 Registration Statement)
• 333-271416 — Registration Number (Related SEC Filing)
• 26-0014658 — IRS Employer Identification Number (ABVC Biopharma)
• NV — State of Incorporation (ABVC Biopharma)

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Registrant
• 20240112 (date) — Filing Date
• S-1 (form) — Filing Type
• 333-271416 (filing_number) — Registration Number
• Nevada (jurisdiction) — State of Incorporation
• 26-0014658 (tax_id) — IRS Employer Identification Number
• 44370 Old Warm Springs Blvd., Fremont, CA 94538 (address) — Principal Executive Offices
• American BriVision (Holding) Corp (company) — Former Company Name

Forward-Looking Statements

• ABVC BioPharma will proceed with a public offering of securities. (ABVC BIOPHARMA, INC.) — high confidence, target: As soon as practicable after this registration statement is declared effective.

FAQ

Industry Context

ABVC Biopharma operates within the pharmaceutical preparations industry, focusing on the development and commercialization of biopharmaceutical products.

Regulatory Implications

The S-1 filing is a standard regulatory requirement under the Securities Act of 1933 for companies planning to offer securities to the public.

What Investors Should Do

1. Review the full S-1 filing for details on the proposed securities offering.
2. Analyze ABVC Biopharma's business strategy and pipeline as outlined in the filing.
3. Track subsequent SEC filings for updates on the offering's progress and potential impact on the company's capital structure.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing of the same type to compare against for this specific registration.

Key Financial Figures

• $0.001 — , a Nevada corporation (the "Company"), $0.001 par value (the "Common Stock"). These s
• $1.5 — e closing price of our common stock was $1.5 per share. Prior to August 3, 2021, our
• $3.50 — price, which shall be the lesser of (i) $3.50 (the " Fixed Price "), (ii) 90% of the
• $2 — rrant") at an initial exercise price of $2 per share and (iii) 30,000 shares of Co
• $0.0001 — 00,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite B
• $6.30 — mon stock at an exercise price equal to $6.30 per share, exercisable until the fifth
• $10.00 — mon stock at an exercise price equal to $10.00 per share, exercisable until the fifth
• $6.25 — n Statement"). The Units were priced at $6.25 per Unit, before underwriting discounts
• $6,875,000 — xpenses, resulting in gross proceeds of $6,875,000. The Offering was conducted on a firm c
• $1.00 — our common stock was below the minimum $1.00 per share required for continued listin
• $2,500,000 — intain stockholders' equity of at least $2,500,000, and the Company's stockholders' equity
• $1,734,507 — the Company's stockholders' equity was $1,734,507 as of March 31, 2023. In accordance wit

Filing Documents

• ea191455-s1_abvcbio.htm (S-1) — 2900KB
• ea191455ex5-1_abvcbio.htm (EX-5.1) — 12KB
• ea191455ex15-1_abvcbio.htm (EX-15.1) — 4KB
• ea191455ex23-2_abvcbio.htm (EX-23.2) — 5KB
• ea191455ex-fee_abvcbio.htm (EX-FILING FEES) — 69KB
• image_001.jpg (GRAPHIC) — 18KB
• image_002.jpg (GRAPHIC) — 18KB
• image_003.jpg (GRAPHIC) — 22KB
• image_004.jpg (GRAPHIC) — 4KB
• image_005.jpg (GRAPHIC) — 12KB
• ex15-1_001.jpg (GRAPHIC) — 22KB
• ex15-1_002.jpg (GRAPHIC) — 4KB
• ex23-1_001.jpg (GRAPHIC) — 9KB
• ex23-1_002.jpg (GRAPHIC) — 4KB
• ex23-1_003.jpg (GRAPHIC) — 15KB
• 0001213900-24-003415.txt (&nbsp;) — 13029KB
• abvc-20230930.xsd (EX-101.SCH) — 128KB
• abvc-20230930_cal.xml (EX-101.CAL) — 53KB
• abvc-20230930_def.xml (EX-101.DEF) — 554KB
• abvc-20230930_lab.xml (EX-101.LAB) — 883KB
• abvc-20230930_pre.xml (EX-101.PRE) — 573KB
• ea191455-s1_abvcbio_htm.xml (XML) — 1652KB

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 27

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29

BUSINESS

BUSINESS 60 MANAGEMENT 75

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 80

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 84 RELATED PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY 85

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 89 SELLING STOCKHOLDERS 91 PLAN OF DISTRIBUTION 92 LEGAL MATTERS 9 4 EXPERTS 9 4 WHERE YOU CAN FIND MORE INFORMATION 9 4 You should rely only on the information contained in this prospectus or in any free writing prospectus that we may specifically authorize to be delivered or made available to you. We and our Underwriter have not authorized anyone to provide you with any information other than that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of these securities in any jurisdiction where the offer is not permitted. Unless the context otherwise requires, the terms "ABVC," "we," "us" and "our" in this prospectus refer to ABVC BIOPHARMA, INC., and "this offering" refers to the offering contemplated in this prospectus. i PROSPECTUS CONVENTIONS Except where the context otherwise requires and for purposes of this prospectus only: "American BriVision Corporation" refers to a Delaware corporation and wholly-owned subsidiary of ABVC; "APR" or "annual percentage rate" refers to the annual rate that is charged to borrowers, including a fixed interest rate and a transaction fee rate, expressed as a single percentage number that represents the actual yearly cost of borrowing over the life of a loan; "BioKey" means BioKey, Inc. refers to a California corporation and wholly-owned subsidiary of ABVC; "BioLite" means BioLite Holding, Inc. re

View Full Filing

View this S-1 filing on SEC EDGAR